Grifols (GIKLY) Return on Capital Employed (2011 - 2020)
Grifols (GIKLY) posted Return on Capital Employed of 46.95% for Q1 2020, up 3.25% quarter-over-quarter from 45.47% in Q4 2019.
Grifols (GIKLY) Return on Capital Employed (2011 - 2020) Analysis & Trends
Grifols (GIKLY) has reported Return on Capital Employed for 9 consecutive years, with 46.95% the latest figure, recorded in Q1 2020.
- Return on Capital Employed for Q1 2020 came in at 46.95%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2020 was 46.95% (changed N/A YoY), and the FY2025 annual result was 15.79%, down 163834.0% from the prior year.
- Return on Capital Employed was 46.95% for Q1 2020 at Grifols, up from 45.47% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 48.91% in Q4 2018 and troughed at 13.07% in Q4 2016.
- Average Return on Capital Employed over 5 years is 30.95%, with a median of 28.78% recorded in 2018.
- Year-over-year, Return on Capital Employed sank 417 bps in 2016 and jumped 2184 bps in 2017.
- Over 5 years, Return on Capital Employed stood at 13.07% in 2016, then jumped by 167 bps to 34.91% in 2017, then surged by 40 bps to 48.91% in 2018, then dropped by 7 bps to 45.47% in 2019, then advanced by 3 bps to 46.95% in 2020.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 46.95% in Q1 2020, 45.47% in Q4 2019, and 48.91% in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 42.94% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 28.18% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 16.47% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.76% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -10.20% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 32.10% |
| Dec 31, 2019 | 29.61% |
| Dec 31, 2018 | 9.38% |
| Sep 30, 2018 | 15.05% |
| Jun 30, 2018 | 13.53% |
| Mar 31, 2018 | 13.89% |
| Dec 31, 2017 | 17.70% |
| Dec 31, 2016 | 13.07% |
| Sep 30, 2016 | 16.09% |
| Jun 30, 2016 | 16.70% |
| Dec 31, 2015 | 17.24% |
| Mar 31, 2015 | 2,823.87% |
| Dec 31, 2014 | 2,866.22% |
| Sep 30, 2014 | 2,938.54% |
| Jun 30, 2014 | 3,016.21% |
| Mar 31, 2014 | 13.14% |
| Dec 31, 2013 | 14.40% |
| Sep 30, 2013 | 13.97% |
| Jun 30, 2013 | 13.62% |
| Mar 31, 2013 | 13.09% |